EUROFINS PANLABS DISCOVERY SERVICES TAIWAN, LTD.

Eurofins Panlabs Discovery Services Taiwan, Ltd. specializes in preclinical safety screening and lead profiling services for pharmaceutical and biotechnology development, delivering high-throughput testing solutions within regulated laboratory environments. Their core expertise lies in the design and execution of in vitro and in vivo safety panels to evaluate pharmacokinetic profiles, toxicological endpoints, and drug candidate viability, supporting early-stage discovery workflows. The company applies rigorous analytical methodologies to identify metabolic liabilities and off-target effects, ensuring compliance with international toxicology standards. Key differentiators include precision in lead optimization workflows, validated assay platforms for metabolic stability and cytotoxicity screening, and integrated data analytics to prioritize candidates for advanced development. The contractor has demonstrated experience supporting the U.S. Department of Health and Human Services, specifically in projects related to translational research and drug safety evaluation under the TRND program. This engagement reflects a focused partnership in advancing novel therapeutics through rigorous preclinical validation, with work centered on safety pharmacology and metabolic profiling of lead compounds. Their primary industry focus is testing laboratories and services, aligning with contract research organization (CRO) functions in drug discovery. They serve the biopharmaceutical sector by providing specialized laboratory services that bridge academic research and clinical development, with an emphasis on safety assessment and pharmacodynamic characterization. Eurofins Panlabs Discovery Services Taiwan, Ltd. operates as a limited liability entity based in New Taipei City, Taiwan. The company holds no federal certifications or accreditations listed in its profile. While geographically located in Asia, its contract activity indicates direct engagement with U.S. federal health research initiatives, positioning it as a specialized international provider of discovery-phase laboratory services to government-funded biomedical programs.